Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cognition Therapeutics ( (CGTX) ) has provided an update.
On March 2, 2026, Cognition Therapeutics announced plans to advance zervimesine (CT1812) into a registrational development path for dementia with Lewy bodies (DLB) psychosis, following receipt of final minutes from a January 21, 2026, FDA Type C meeting. The move builds on Phase 2 SHIMMER trial data in mild-to-moderate DLB showing robust benefit on neuropsychiatric symptoms such as hallucinations and agitation, with an 86% slowing of decline on the NPI-12 versus placebo and no apparent worsening of motor function.
The company plans its next DLB study to randomize patients to 100 mg of oral zervimesine or placebo, using validated endpoints to measure hallucinations, delusions, and behavioral symptoms, with an open-label extension to follow. If the FDA’s Division of Psychiatry ultimately agrees that this constitutes a registrational program, zervimesine could become the first approved treatment for DLB psychosis, addressing a large unmet need in a population that often cannot tolerate traditional antipsychotics and faces high care burdens and early institutionalization.
The most recent analyst rating on (CGTX) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Cognition Therapeutics stock, see the CGTX Stock Forecast page.
Spark’s Take on CGTX Stock
According to Spark, TipRanks’ AI Analyst, CGTX is a Neutral.
The score is held down primarily by weak financial performance (minimal revenue, large losses, and significant cash burn) and a soft technical setup (below key moving averages with negative MACD). A low-debt balance sheet and a positive FDA interaction supporting progression toward a Phase 2b trial provide partial offsets, but not enough to materially lift the overall risk profile.
To see Spark’s full report on CGTX stock, click here.
More about Cognition Therapeutics
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative small-molecule therapeutics for age-related degenerative disorders of the central nervous system. Its lead candidate, zervimesine (CT1812), is an investigational oral therapy targeting sigma-2 receptors for diseases including dementia with Lewy bodies, Alzheimer’s disease and geographic atrophy secondary to dry age-related macular degeneration, supported in part by substantial grants from the U.S. National Institute on Aging.
Average Trading Volume: 903,586
Technical Sentiment Signal: Sell
Current Market Cap: $96.22M
For detailed information about CGTX stock, go to TipRanks’ Stock Analysis page.